出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年1月
Neuromodulation Market – Global Forecast to 2028
ニューロモジュレーション市場 : タイプ [内部 (脊髄刺激、脳深部刺激)、外部 (経頭蓋磁気刺激)]、用途 (振戦、てんかん、パーキンソン病、うつ病、胃不全麻痺)＆地域別 – 2028年までの世界予測
Neuromodulation Market by Type (Internal (Spinal Cord Stimulation, Deep Brain Stimulation), External (Transcranial Magnetic Stimulation), Application (Tremor, Epilepsy, Parkinson’s Disease, Depression, Gastroparesis), and Region – Global Forecast to 2028
| ページ数 | 204 |
| 図表数 | 234 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global neuromodulation market is valued at an estimated USD 6.2 billion in 2023 and is projected to reach USD 11.0 billion by 2028, at a CAGR of 12.0% during the forecast period.
世界のニューロモジュレーション市場は、2023 年に推定 62 億米ドルと評価され、予測期間中の CAGR 12.0% で、2028 年までに 110 億米ドルに達すると予測されています。
Market growth is driven by factors such as prevalence of neurological disorders and nerve injuries, increasing focus on development of advanced neuromodulation and neurostimulation technologies, growing geriatric population and subsequent increase in prevalence of neurological disorders, government support for research on neurological disorders, availability of reimbursement of neuromodulation devices, collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices.
“The internal neuromodulation dominated the neuromodulation market, by type.”
Based on type, global neuromodulation market is categorized into internal and external neuromodulation on type. In 2022, internal neuromodulation contributed largest of neuromodulation market. Market growth is largely driven by the long term associated with cost saving, minimally invasive nature, reduced physical impact and improved quality of life.
“Deep Brain Stimulation segment to grow at a considerable rate among internal neuromodulation type during the forecast period.”
The neuromodulation market is segmented into into deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electrical stimulation on type. The increasing incidences of targeted diseases such as Parkinson’s disease & depression and companies are focusing product launches, approvals in this segment. These driving factors are the boost market growth.
“Asia Pacific: The fastest-growing region in the neuromodulation market.”
The global neuromodulation market is segmented into five regions – North America, Europe, the Asia Pacific, Rest of the World. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the neuromodulation market. The high growth in the region is due to the primarily be attributed to the increasing geriatric population, and high disease burden of neurological disorders among senior population.
The break-up of the profile of primary participants in the neuromodulation market:
• By Company Type: Tier 1 – 28%, Tier 2 – 42%, and Tier 3 – 30%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 46%, Europe – 25%, Asia Pacific – 18%, and the Rest of the World – 11%
The key players in this market are Medtronic (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), LivaNova (UK), NeuroPace (US), Neuronetics (US), Helius Medical Technologies (US), Renishaw (UK), Bioinduction (UK), Axonics (US), Nevro Corporation (US), BlueWind Medical (Israel), Aleva Neurotherapeutics (Switzerland), GiMer Medical (Taiwan), NeuroSigma (US), BioWaveGo USA (US), Synapse Biomedical (US), Theranica Bio-Electronics (Israel), MicroTransponder (US), Soterix Medical (US), Saluda Medical (US), Electrocore, Inc. (US), Magstim (UK), BIOTRONIK (Germany), tVNS Technologies (Germany).
Research Coverage:
This research report categorizes the neuromodulation market by type (internal, external), internal (spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES)), application ((spinal cord stimulations (failed back syndrome, chronic pain, ischemia), deep brain stimulation (Parkinson’s disease, tremors, depression, other DBS application), sacral nerve stimulation (urine incontinence, fecal incontinence), vagus nerve stimulation (epilepsy, other epilepsy application), gastric electrical stimulation (gastroparesis, obesity), transcutaneous electrical nerve stimulation (Treatment-resistant Depression and other TENS application), transcranial magnetic stimulation (Migranie, Depression) and region (North America, Europe, Asia Pacific, Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, opportunities, and challenges, influencing the growth of the neuromodulation market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the neuromodulation market. This report covers the competitive analysis of upcoming startups in the neuromodulation market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (the rising prevalence of neurological disorders, expanding applications of neuromodulation, and rising awareness of neurodegenerative disorders), opportunities (Widening application scope of neuromodulation, large population and increasing healthcare expenditure in emerging economies), and challenges (stringent regulatory frameworks and time-consuming approval processes, shortage of trained professionals, product recalls ) influencing the growth of the neuromodulation market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the neuromodulation market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the neuromodulation market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the neuromodulation market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Medtronic (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), LivaNova (UK), NeuroPace (US), among others in the neuromodulation market strategies.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED 33
1.3.3 CURRENCY CONSIDERED 33
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Secondary sources 37
2.1.2 PRIMARY DATA 37
2.1.2.1 Key data from primary sources 38
2.1.2.2 Key industry insights 39
2.1.2.3 Breakdown of primary interviews: supply- and demand-side participants 39
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 40
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE) 40
2.2 MARKET SIZE ESTIMATION 41
2.2.1 BOTTOM-UP APPROACH 41
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 41
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 42
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION 44
2.4 MARKET SHARE ASSESSMENT 45
2.5 ASSUMPTIONS 45
2.6 RISK ASSESSMENT 45
2.7 RESEARCH LIMITATIONS 46
2.7.1 METHODOLOGY-RELATED LIMITATIONS 46
2.7.2 SCOPE-RELATED LIMITATIONS 46
2.8 IMPACT OF RECESSION ON NEUROMODULATION MARKET 46
3 EXECUTIVE SUMMARY 47
FIGURE 8 NEUROMODULATION MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 9 NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 10 NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 11 NEUROMODULATION MARKET, BY REGION 49
4 PREMIUM INSIGHTS 50
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET 50
FIGURE 12 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS 50
4.2 NORTH AMERICAN NEUROMODULATION MARKET, BY TYPE AND COUNTRY 51
FIGURE 13 INTERNAL NEUROMODULATION SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF NORTH AMERICAN MARKET IN 2022 51
4.3 NEUROMODULATION MARKET, BY COUNTRY 52
FIGURE 14 CHINA TO REGISTER HIGHEST CAGR IN NEUROMODULATION MARKET DURING FORECAST PERIOD 52
4.4 NEUROMODULATION MARKET, BY REGION 53
FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 53
4.5 NEUROMODULATION MARKET: DEVELOPED VS. DEVELOPING MARKETS 53
FIGURE 16 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 17 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES, AND TRENDS 54
5.2.1 DRIVERS 55
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries 55
5.2.1.2 Increasing focus on development of advanced neuromodulation and neurostimulation technologies 55
5.2.1.3 Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices 56
5.2.1.4 Growing geriatric population and subsequent increase in prevalence of neurological disorders 56
5.2.1.5 Availability of reimbursements for neuromodulation devices 56
5.2.1.6 Government-led support for research on neurological disorders 57
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of neuromodulation procedures 57
5.2.2.2 Preference for drug therapies over neuromodulation products 57
5.2.2.3 Adverse effects and complications associated with neuromodulation devices 58
TABLE 1 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Large population and increasing healthcare expenditure in emerging economies 58
5.2.3.2 Widening application scope of neuromodulation 58
TABLE 2 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS 59
FIGURE 18 PUBLISHED RESEARCH PAPERS, 2013–2022 59
5.2.4 CHALLENGES 60
5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices 60
5.2.4.2 Shortage of trained professionals 60
5.2.4.3 Product recalls 60
TABLE 3 MAJOR PRODUCT RECALLS 60
5.2.5 TRENDS 61
5.2.5.1 Role of artificial intelligence (AI) in advancing neuromodulation 61
5.3 VALUE CHAIN ANALYSIS 61
FIGURE 19 NEUROMODULATION MARKET: VALUE CHAIN ANALYSIS 61
5.3.1 RESEARCH AND DEVELOPMENT (R&D) 62
5.3.2 MANUFACTURING AND ASSEMBLY 62
5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 62
5.4 SUPPLY CHAIN ANALYSIS 62
FIGURE 20 DIRECT DISTRIBUTION—PREFERRED STRATEGY OF PROMINENT COMPANIES 63
5.5 TECHNOLOGY ANALYSIS 63
5.6 PORTER’S FIVE FORCES ANALYSIS 64
TABLE 4 NEUROMODULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 64
5.6.1 THREAT OF NEW ENTRANTS 64
5.6.2 INTENSITY OF COMPETITIVE RIVALRY 64
5.6.3 BARGAINING POWER OF BUYERS 64
5.6.4 BARGAINING POWER OF SUPPLIERS 64
5.6.5 THREAT OF SUBSTITUTES 65
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 65
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 65
TABLE 5 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS BY END USER 65
5.7.2 BUYING CRITERIA 65
FIGURE 22 KEY BUYING CRITERIA BY END USER 65
5.8 REGULATORY LANDSCAPE 66
TABLE 6 LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION 66
5.8.1 REGULATORY LANDSCAPE, BY REGION 67
5.8.1.1 North America 67
5.8.1.1.1 US 67
TABLE 7 CLASSIFICATION OF MEDICAL DEVICES BY US FDA 67
5.8.1.2 Europe 67
5.8.1.3 Asia Pacific 68
5.8.1.3.1 India 68
5.8.1.3.2 China 68
TABLE 8 NMPA MEDICAL DEVICES CLASSIFICATION 68
5.8.1.4 Japan 68
TABLE 9 JAPAN: CLASSIFICATION OF MEDICAL DEVICES 68
5.9 PATENT ANALYSIS 69
5.10 KEY CONFERENCES AND EVENTS, 2024–2025 69
TABLE 10 NEUROMODULATION MARKET: LIST OF CONFERENCES AND EVENTS, 2024–2025 69
5.11 PRICING ANALYSIS 71
TABLE 11 PRICE RANGE OF NEUROMODULATION DEVICES AND PROCEDURES, 2022 71
5.12 TRADE ANALYSIS 72
TABLE 12 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION) 72
TABLE 13 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION) 72
5.13 ECOSYSTEM MAPPING 73
FIGURE 23 NEUROMODULATION MARKET: ECOSYSTEM MAPPING 73
TABLE 14 COMPANIES AND THEIR ROLES IN NEUROMODULATION ECOSYSTEM 73
FIGURE 24 KEY PLAYERS IN NEUROMODULATION MARKET 74
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
6 NEUROMODULATION MARKET, BY TYPE 75
6.1 INTRODUCTION 76
TABLE 15 NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 76
6.2 INTERNAL NEUROMODULATION 76
TABLE 16 INTERNAL: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 77
TABLE 17 INTERNAL: NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.2.1 SPINAL CORD STIMULATION 77
6.2.1.1 Growing incidence of spinal cord injuries to fuel market growth 77
TABLE 18 SPINAL CORD STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 79
TABLE 19 INTERNAL: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2021–2028 (USD MILLION) 79
6.2.2 DEEP BRAIN STIMULATION 80
6.2.2.1 Growing use to control debilitating symptoms caused by neurological disorders to drive market 80
TABLE 20 DEEP BRAIN STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 81
TABLE 21 INTERNAL: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2021–2028 (USD MILLION) 81
6.2.3 VAGUS NERVE STIMULATION 81
6.2.3.1 Rising geriatric population and high incidence of epilepsy to drive market 81
TABLE 22 VAGUS NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 82
TABLE 23 INTERNAL: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION) 82
6.2.4 SACRAL NERVE STIMULATION 82
6.2.4.1 Widening application scope of sacral nerve stimulation to drive market 82
TABLE 24 SACRAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 83
TABLE 25 INTERNAL: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION) 83
6.2.5 GASTRIC ELECTRICAL STIMULATION 84
6.2.5.1 Growing number of people suffering from severe gastroesophageal reflux disease (GERD) and gastroparesis to fuel market growth 84
TABLE 26 GASTRIC ELECTRICAL STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 84
TABLE 27 INTERNAL: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY REGION, 2021–2028 (USD MILLION) 84
6.3 EXTERNAL NEUROMODULATION 85
TABLE 28 EXTERNAL NEUROMODULATION: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 85
TABLE 29 EXTERNAL NEUROMODULATION: NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION) 85
6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 86
6.3.1.1 Extensive use in healthcare sector, low cost, and ease of use to fuel market growth 86
TABLE 30 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 86
TABLE 31 EXTERNAL: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION) 87
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 87
6.3.2.1 Minimal patient discomfort associated with transcranial magnetic stimulation (TMS) to support demand 87
TABLE 32 TRANSCRANIAL MAGNETIC STIMULATION DEVICE OFFERED BY MAJOR COMPANIES 87
TABLE 33 EXTERNAL: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2021–2028 (USD MILLION) 88
6.3.3 RESPIRATORY ELECTRICAL STIMULATION 88
6.3.3.1 High treatment efficacy to fuel market growth 88
TABLE 34 RESPIRATORY ELECTRICAL STIMULATION DEVICE OFFERED BY MAJOR COMPANIES 88
TABLE 35 EXTERNAL: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2021–2028 (USD MILLION) 89
7 NEUROMODULATION MARKET, BY APPLICATION 90
7.1 INTRODUCTION 91
7.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION 91
TABLE 36 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 91
7.2.1 CHRONIC PAIN 91
7.2.1.1 High incidence of chronic pain to support market growth 91
TABLE 37 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2021–2028 (USD MILLION) 92
7.2.2 FAILED BACK SURGERY SYNDROME (FBSS) 92
7.2.2.1 Increasing incidence of failed back surgery syndrome (FBSS) with rising number of surgeries annually to drive demand 92
TABLE 38 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2021–2028 (USD MILLION) 93
7.2.3 ISCHEMIA 93
7.2.3.1 High effectiveness of neuromodulation for ischemia treatment to support market growth 93
TABLE 39 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2021–2028 (USD MILLION) 93
7.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION 94
TABLE 40 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 94
7.3.1 PARKINSON’S DISEASE 94
7.3.1.1 Rising incidence of Parkinson’s disease and growing R&D for innovation to drive market 94
TABLE 41 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2021–2028 (USD MILLION) 95
7.3.2 TREMORS 95
7.3.2.1 High efficacy of deep brain stimulation (DBS) in treating tremors to boost demand 95
TABLE 42 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2021–2028 (USD MILLION) 95
7.3.3 DEPRESSION 96
7.3.3.1 Rising research and clinical studies related to depression treatment to drive market 96
TABLE 43 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 96
7.3.4 OTHER DBS APPLICATIONS 96
TABLE 44 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 97
7.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION 97
TABLE 45 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 97
7.4.1 URINE INCONTINENCE 98
7.4.1.1 High incidence of urine incontinence to create growth opportunities 98
TABLE 46 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2021–2028 (USD MILLION) 98
7.4.2 FECAL INCONTINENCE 98
7.4.2.1 Reduced symptom recurrence with use of SNS in fecal incontinence treatment to drive demand 98
TABLE 47 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2021–2028 (USD MILLION) 99
7.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION (VNS), BY APPLICATION 99
TABLE 48 NEUROMODULATION MARKET FOR VAGUS NERVE SIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 99
7.5.1 EPILEPSY 99
7.5.1.1 Advantages associated with VNS in epilepsy treatment to propel market growth 99
TABLE 49 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2021–2028 (USD MILLION) 100
7.5.2 OTHER VNS APPLICATIONS 100
TABLE 50 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 100
7.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 101
TABLE 51 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 101
7.6.1 GASTROPARESIS 101
7.6.1.1 Reduced hospitalization time for patients affected by gastroparesis by GES treatment to drive market 101
TABLE 52 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2021–2028 (USD MILLION) 101
7.6.2 OBESITY 102
7.6.2.1 High prevalence of obesity and risks associated with gastric bypass to fuel demand 102
TABLE 53 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION) 102
7.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION 102
TABLE 54 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 102
7.7.1 TREATMENT-RESISTANT DEPRESSION 103
7.7.1.1 Increasing prevalence of depression to boost market growth 103
TABLE 55 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 103
7.7.2 OTHER TENS APPLICATIONS 103
TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 104
7.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION 104
TABLE 57 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 104
TABLE 58 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 104
7.8.1 DEPRESSION 105
7.8.1.1 High effectiveness of TMS and increased acceptance among patients to drive market 105
TABLE 59 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 105
7.8.2 MIGRAINE 105
7.8.2.1 High prevalence of migraine to support market growth 105
TABLE 60 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2021–2028 (USD MILLION) 106
7.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION 106
7.9.1 SPINAL CORD INJURY 106
7.9.1.1 Rising incidence of spinal cord injuries to fuel demand 106
TABLE 61 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2021–2028 (USD MILLION) 106
8 NEUROMODULATION MARKET, BY REGION 107
8.1 INTRODUCTION 108
TABLE 62 NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION) 108
8.2 NORTH AMERICA 108
FIGURE 26 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT 109
TABLE 63 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 64 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 65 NORTH AMERICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 66 NORTH AMERICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 67 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 68 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 69 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 70 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 71 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 72 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 73 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 113
8.2.1 US 113
8.2.1.1 Large presence of prominent players to drive market 113
FIGURE 27 PROJECTED NUMBER OF PEOPLE WITH ALZHEIMER’S DEMENTIA IN US, 2020–2060 (MILLION) 114
TABLE 74 US FDA-APPROVED PRODUCTS, 2019–2022 114
TABLE 75 US: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 76 US: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 77 US: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 115
8.2.2 CANADA 116
8.2.2.1 Rising healthcare expenditure and increasing prevalence of chronic diseases to drive demand 116
TABLE 78 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA, 2016–2031 116
TABLE 79 CANADA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 80 CANADA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 81 CANADA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 118
8.2.3 NORTH AMERICAN NEUROMODULATION MARKET: RECESSION IMPACT 118
8.3 EUROPE 118
TABLE 82 PREVALENCE OF DEMENTIA, BY COUNTRY, 2018 & 2050 119
TABLE 83 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 84 EUROPE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 85 EUROPE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 86 EUROPE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 87 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 88 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 89 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 90 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 91 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 92 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 123
TABLE 93 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 123
8.3.1 GERMANY 123
8.3.1.1 Increasing healthcare expenditure and presence of favorable reimbursement policies to drive market 123
TABLE 94 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 95 GERMANY: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 96 GERMANY: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 125
8.3.2 UK 125
8.3.2.1 Rising healthcare expenditure and high public- and private-sector investments to fuel market growth 125
TABLE 97 UK: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 98 UK: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 99 UK: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 126
8.3.3 FRANCE 126
8.3.3.1 Availability of insurance and favorable healthcare reforms to drive market 126
TABLE 100 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 101 FRANCE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 102 FRANCE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 128
8.3.4 ITALY 128
8.3.4.1 Easy access to healthcare services to create lucrative opportunities for market 128
TABLE 103 ITALY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 104 ITALY: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 105 ITALY: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 129
8.3.5 SPAIN 130
8.3.5.1 Growing government-led initiatives related to healthcare to support market growth 130
TABLE 106 SPAIN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 107 SPAIN: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 108 SPAIN: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 131
8.3.6 REST OF EUROPE 131
TABLE 109 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 110 REST OF EUROPE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 111 REST OF EUROPE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 132
8.3.7 EUROPEAN NEUROMODULATION MARKET: RECESSION IMPACT 132
8.4 ASIA PACIFIC 133
FIGURE 28 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT 133
TABLE 112 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 113 ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 114 ASIA PACIFIC: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 115 ASIA PACIFIC: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 116 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 135
TABLE 117 ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 135
TABLE 118 SIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 119 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 120 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 121 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 122 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 137
8.4.1 JAPAN 137
8.4.1.1 Increasing prevalence of neurological disorders to drive demand 137
TABLE 123 JAPAN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 124 JAPAN: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 125 JAPAN: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 139
8.4.2 CHINA 139
8.4.2.1 Growing geriatric population to fuel demand 139
TABLE 126 CHINA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 127 CHINA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 128 CHINA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 140
8.4.3 INDIA 140
8.4.3.1 Improvements in healthcare infrastructure to contribute to market growth 140
TABLE 129 INDIA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 130 INDIA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 131 INDIA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 141
8.4.4 REST OF ASIA PACIFIC 142
TABLE 132 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 133 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 134 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 143
8.4.5 ASIA PACIFIC NEUROMODULATION MARKET: RECESSION IMPACT 143
8.5 ROW 144
TABLE 135 ROW: NEUROMODULATION MARKET, BY COUNTRY/REGION, 2021–2028 (USD MILLION) 144
TABLE 136 ROW: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 137 ROW: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 138 ROW: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 139 ROW: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 145
TABLE 140 ROW: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 141 ROW: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 142 ROW: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 143 ROW: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 144 ROW: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 145 ROW: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 147
8.5.1 LATIN AMERICA 148
8.5.1.1 Increasing cases of depressive and post-traumatic stress disorders to drive demand 148
TABLE 146 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 147 LATIN AMERICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 148 LATIN AMERICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 149
8.5.2 MIDDLE EAST & AFRICA 149
8.5.2.1 Improvements in healthcare infrastructure and growing awareness regarding neuromodulation to drive market 149
TABLE 149 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 150 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 151 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 151
8.5.3 GCC COUNTRIES 151
TABLE 152 GCC COUNTRIES: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 153 GCC COUNTRIES: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 154 GCC COUNTRIES: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
8.5.4 ROW NEUROMODULATION MARKET: RECESSION IMPACT 152
9 COMPETITIVE LANDSCAPE 153
9.1 OVERVIEW 153
9.2 STRATEGIES ADOPTED BY KEY PLAYERS 153
TABLE 155 NEUROMODULATION MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 153
9.3 REVENUE SHARE ANALYSIS, 2020–2022 154
FIGURE 29 NEUROMODULATION MARKET: REVENUE ANALYSIS OF FIVE KEY PLAYERS, 2020–2022 154
9.4 MARKET SHARE ANALYSIS, 2022 155
TABLE 156 NEUROMODULATION MARKET: DEGREE OF COMPETITION 155
9.5 COMPANY EVALUATION MATRIX, 2022 156
9.5.1 STARS 156
9.5.2 EMERGING LEADERS 156
9.5.3 PERVASIVE PLAYERS 156
9.5.4 PARTICIPANTS 156
FIGURE 30 NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX, 2022 157
9.5.5 COMPANY FOOTPRINT 157
TABLE 157 OVERALL COMPANY FOOTPRINT 157
TABLE 158 COMPANY REGION FOOTPRINT 158
TABLE 159 COMPANY TYPE FOOTPRINT 159
9.6 START-UPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES) EVALUATION MATRIX, 2022 160
9.6.1 PROGRESSIVE COMPANIES 160
9.6.2 STARTING BLOCKS 160
9.6.3 RESPONSIVE COMPANIES 160
9.6.4 DYNAMIC COMPANIES 161
FIGURE 31 NEUROMODULATION MARKET: START-UPS/SMES EVALUATION MATRIX, 2022 161
9.6.5 COMPETITIVE BENCHMARKING 162
TABLE 160 NEUROMODULATION MARKET: LIST OF KEY START-UPS/SMES 162
9.7 COMPETITIVE SCENARIOS AND TRENDS 162
9.7.1 PRODUCT LAUNCHES & APPROVALS 162
TABLE 161 NEUROMODULATION MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2023 162
9.7.2 DEALS 163
TABLE 162 NEUROMODULATION MARKET: DEALS, 2020–2023 163
10 COMPANY PROFILES 164
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
10.1 KEY PLAYERS 164
10.1.1 MEDTRONIC PLC 164
TABLE 163 MEDTRONIC PLC: COMPANY OVERVIEW 164
FIGURE 32 MEDTRONIC PLC: COMPANY SNAPSHOT 165
TABLE 164 MEDTRONIC PLC: PRODUCT APPROVALS 167
TABLE 165 MEDTRONIC PLC: DEALS 167
10.1.2 BOSTON SCIENTIFIC CORPORATION 169
TABLE 166 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 169
FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 170
TABLE 167 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES AND APPROVALS 171
TABLE 168 BOSTON SCIENTIFIC CORPORATION: DEALS 172
10.1.3 ABBOTT LABORATORIES 173
TABLE 169 ABBOTT LABORATORIES: COMPANY OVERVIEW 173
FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT 174
TABLE 170 ABBOTT LABORATORIES: PRODUCT LAUNCHES AND APPROVALS 175
10.1.4 LIVANOVA PLC 176
TABLE 171 LIVANOVA PLC: COMPANY OVERVIEW 176
FIGURE 35 LIVANOVA PLC: COMPANY SNAPSHOT 177
TABLE 172 LIVANOVA PLC: PRODUCT APPROVALS 178
TABLE 173 LIVANOVA PLC: DEALS 178
10.1.5 NEVRO CORPORATION 179
TABLE 174 NEVRO CORPORATION: COMPANY OVERVIEW 179
FIGURE 36 NEVRO CORPORATION: COMPANY SNAPSHOT 179
TABLE 175 NEVRO CORPORATION: PRODUCT APPROVALS 180
TABLE 176 NEVRO CORPORATION: DEALS 180
10.1.6 NEUROSIGMA, INC. 181
TABLE 177 NEUROSIGMA, INC.: COMPANY OVERVIEW 181
TABLE 178 NEUROSIGMA, INC.: PRODUCT LAUNCHES & APPROVALS 182
TABLE 179 NEUROSIGMA, INC.: DEALS 182
TABLE 180 NEUROSIGMA, INC.: OTHERS 183
10.1.7 NEUROPACE, INC. 184
TABLE 181 NEUROPACE, INC.: COMPANY OVERVIEW 184
FIGURE 37 NEUROPACE, INC.: COMPANY SNAPSHOT 184
TABLE 182 NEUROPACE, INC.: PRODUCT LAUNCHES & APPROVALS 185
TABLE 183 NEUROPACE, INC.: OTHERS 185
10.1.8 SOTERIX MEDICAL INC. 186
TABLE 184 SOTERIX MEDICAL INC.: COMPANY OVERVIEW 186
TABLE 185 NEUROPACE, INC.: OTHERS 187
10.1.9 SYNAPSE BIOMEDICAL INC. 188
TABLE 186 SYNAPSE BIOMEDICAL INC.: COMPANY OVERVIEW 188
10.1.10 ALEVA NEUROTHERAPEUTICS SA 189
TABLE 187 ALEVA NEUROTHERAPEUTICS SA: COMPANY OVERVIEW 189
TABLE 188 ALEVA NEUROTHERAPEUTICS SA: PRODUCT APPROVALS 189
10.1.11 THERANICA BIO-ELECTRONICS LTD. 190
TABLE 189 THERANICA BIO-ELECTRONICS LTD.: COMPANY OVERVIEW 190
TABLE 190 THERANICA BIO-ELECTRONICS LTD.: PRODUCT APPROVALS 190
10.1.12 NEURONETICS 191
TABLE 191 NEURONETICS: COMPANY OVERVIEW 191
FIGURE 38 NEURONETICS: COMPANY SNAPSHOT 192
10.1.13 AXONICS 193
TABLE 192 AXONICS: COMPANY OVERVIEW 193
FIGURE 39 AXONICS: COMPANY SNAPSHOT 193
TABLE 193 AXONICS: PRODUCT APPROVALS 194
TABLE 194 AXONICS: DEALS 194
10.1.14 BIOINDUCTION 195
TABLE 195 BIOINDUCTION: COMPANY OVERVIEW 195
10.2 OTHER PLAYERS 196
10.2.1 GIMER MEDICAL 196
10.2.2 NALU MEDICAL INC. 196
10.2.3 HELIUS MEDICAL TECHNOLOGIES 197
10.2.4 MICROTRANSPONDER 197
10.2.5 MAGSTIM 198
10.2.6 ELECTROCORE, INC. 198
10.2.7 RENISHAW PLC 199
10.2.8 TVNS TECHNOLOGIES GMBH 199
10.2.9 BIOWAVEGO USA 200
10.2.10 BIOTRONIK 200
10.2.11 SALUDA MEDICAL PTY LTD. 201
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
11 APPENDIX 202
11.1 DISCUSSION GUIDE 202
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 207
11.3 CUSTOMIZATION OPTIONS 209
11.4 RELATED REPORTS 209
11.5 AUTHOR DETAILS 210